EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Impact of Molecular Evaluations in the Biology, Diagnosis, and Prognostication of Patients With Mastocytosis

Gregor Hoermann, Alberto Orfao, Jonathan J Lyons, Yannick Chantran, Sigurd Broesby-Olsen, Vito Sabato, Michel Arock

The Journal of Allergy and Clinical Immunology: In Practice · 2026-01 · 14 (1) · 1-16

DOI: 10.1016/j.jaip.2025.07.055 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026-01. Verfasst von Gregor Hoermann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; MLL Munich Leukemia Laboratory, Munich, German…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-kit, Mastocytosis, Mastocytosis, Systemic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, FWO, ISCIII.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mastocytosis represents a group of rare clonal disorders characterized by accumulation of neoplastic mast cells. Disease presentations range from indolent to highly aggressive forms. The discovery of somatic mutations in KIT, particularly KIT p.D816V, has revolutionized diagnosis, classification, and management of mastocytosis. KIT p.D816V, found in >85% of systemic mastocytosis (SM) cases, drives disease progression through constitutive activation of the KIT receptor. Highly sensitive techniques, such as allele-specific oligonucleotide quantitative polymerase chain reaction (PCR), digital PCR, and Flow-Super Rolling Circle Amplification, have enhanced detection of KIT p.D816V, whereas next-generation sequencing has allowed detection of other mutations, improving not only diagnostics and prognostication, but also monitoring of KIT p.D816V-targeted therapies. Of note, higher KIT p.D816V allele burdens, together with the presence of additional mutations in genes such as DNMT3A (DNA (cytosine-5)-methyltransferase 3α), SRSF2 (serine/arginine-rich splicing factor 2), ASXL1 (additional sex combs-like 1), EZH2 (enhancer of zeste homolog 2), and/or RUNX1 (runt-related transcription factor 1), termed high risk mutations, correlate with advanced SM subtypes. Hereditary α-tryptasemia (HαT) is a genetic condition where increased TPSAB1 gene copy encoding α-tryptase usually leads to elevated serum tryptase. The incidence of HαT is increased in mastocytosis and may exacerbate mediator-related symptoms, emphasizing the importance of searching for this genetic condition in mastocytosis. To conclude, despite remaining challenges in standardization, molecular investigations may now improve diagnostics, prognostication, and treatment monitoring in mastocytosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-kitMastocytosisMastocytosis, SystemicHumansMutationPrognosisDNA Methyltransferase 3ASerine-Arginine Splicing Factors

Stichwörter der Autor:innen

Allele-specific quantitative PCRDiagnosisDigital PCRKIT p.D816V mutantMastocytosisMonitoringNext generation sequencingPrognosis

Substanzen

Proto-Oncogene Proteins c-kitKIT protein, humanDNA Methyltransferase 3ASerine-Arginine Splicing FactorsSRSF2 protein, humanDNMT3A protein, human

Autor:innen und Institutionen

  • Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; MLL Munich Leukemia Laboratory, Munich, Germany. Electronic address: gregor.hoermann@mll.com.
  • Servicio Central de Citometria, Centro de Investigacion del Cancer (CIC; CSIC/USAL), CIBERONC and Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain; Department of Medicine, University of Salamanca, Salamanca…
  • Division of Allergy & Immunology, Department of Medicine, University of California San Diego, La Jolla, Calif; Veterans Affairs San Diego Healthcare System, La Jolla, Calif.
  • Department of Biological Immunology, Saint-Antoine Hospital, DMU BioGeMH, AP-HP, Sorbonne University, Paris, France; Platform of Molecular Analysis for Mastocytosis and MCAS, ECNM Reference Center for c-KIT Mutations an…
  • Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.
  • Immunology-Allergology-Rheumatology, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp University Hospital and Infla-Med Centre of Excellence Antwerp University, Antwerpen, Belgium.

Förderung

  • NIAID NIH HHS
  • FWO
  • ISCIII
  • NIAID

Zitieren

APA

Hoermann, G., Orfao, A., Lyons, J. J., Chantran, Y., Broesby-Olsen, S., Sabato, V., & Arock, M. (2026). Impact of Molecular Evaluations in the Biology, Diagnosis, and Prognostication of Patients With Mastocytosis. The Journal of Allergy and Clinical Immunology: In Practice, 14(1), 1-16. https://doi.org/10.1016/j.jaip.2025.07.055

Vancouver

Hoermann G, Orfao A, Lyons JJ, Chantran Y, Broesby-Olsen S, Sabato V, et al. Impact of Molecular Evaluations in the Biology, Diagnosis, and Prognostication of Patients With Mastocytosis. The Journal of Allergy and Clinical Immunology: In Practice. 2026;14(1):1-16. doi:10.1016/j.jaip.2025.07.055

BibTeX
@article{Hoermann2026,
  author = {Hoermann, Gregor and Orfao, Alberto and Lyons, Jonathan J and Chantran, Yannick and Broesby-Olsen, Sigurd and Sabato, Vito and Arock, Michel},
  title = {Impact of Molecular Evaluations in the Biology, Diagnosis, and Prognostication of Patients With Mastocytosis},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2026},
  volume = {14},
  number = {1},
  pages = {1--16},
  doi = {10.1016/j.jaip.2025.07.055}
}
Kostenlos starten →